Using our preclinical model of patient-derived melanoma cells cultured in stem cell medium (SCM), we investigated effects of targeted drugs, vemurafenib and trametinib, on MITF level and expression of MITF-dependent pigmentation/differentiation genes. This evidence concerns the gene MITF and melanoma.